Article info
Extended report
Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32)
- Dr Torsten Witte, Department of Clinical Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany; witte.torsten{at}mh-hannover.de
Citation
Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32)
Publication history
- Accepted May 22, 2007
- First published June 8, 2007.
Online issue publication
January 11, 2008
Article Versions
- Previous version (8 June 2007).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 BMJ Publishing Group and European League Against Rheumatism